A Comparative Study of the Detection of cAMP response element binding protein (CREB) in the Peripheral Blood of Alzheimer's Patients and the Healthy subjects as a Biomarker for the diagnosis of Alzheimer by Chitsaz, Ahmad et al.
ORIGINAL ARTICLE
1 1Masih Falahatian  *, Ahmad Chitsaz
1 School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
 
* Corresponding Author: Masih Falahatian, Email: masih.falahatian@gmail.com
ABSTRACT
Published by Mehrabani Publishing LLC.  














Internal Medicine and Medical Investigation Journal
E-ISSN: 2474-7750
Homepage: www.imminv.com
A Comparative Study of the Detection of cAMP response element binding protein (CREB) in 
the Peripheral Blood of Alzheimer's Patients and the Healthy subjects as a Biomarker for 
the diagnosis of Alzheimer
INTRODUCTION
Dementia or cognitive disorder is one of the most important 
symptoms of Alzheimer's disease (AD) which occurs due to 
neurodegeneration in the central nervous system. Alzheim-
er's disease is most often observed in elderly people and as 
reported, the risk of developing Alzheimer at the age of 65 to 
100 in males is 33% and in females is 45% (1). Consequent-
ly, the Alzheimer's disease causes many economic loss and 
health issues for the society.
    Various research have suggested that the period of the 
Alzheimer's disease is a chronic period and neurodegenera-
tion has begun many years before the appearance of the 
clinical symptoms (2). Moreover, the fact that the process of 
the illness is prolonged provides the time needed to study the 
causes and symptoms of the disease. Having known the fact 
that hyperphosphorylation of the tau proteins, the formation 
of intracellular neurofibrillary coils and formation of 
beta-amyloid plaques in extracellular space are the main 
reasons of the long period of the development of Alzheim-
er’s disease (3,4). Considering the long period of the disease, 
the early diagnosis of the Alzheimer is of utmost importance 
and nowadays the researchers try to study and discover 
novel methods and specifically biomarkers by implementing 
them we are enable to diagnose the disease in its preliminary 
stages (5).
    The binding protein to the responding component to the 
cyclic adenosine monophosphate (cAMP)-response element 
binding (CREB) cyclic proteins are a member of proteins the 
function of them is the growth, differentiation, and survival 
of vital neurons and are widely spread in the nervous system 
(6). Various research have shown that CREB has a substan-
tial role in neuronal axonal growth and conduction and also 
releasing neurotransmitters (7 – 10) which has made this 
factor an important factor in neurodegeneration disorder 
pathophysiology and in Alzheimer’s disease in specific. In 
this field, there have been research, which suggest the 
decrease of this protein in the brain of the individuals 
diagnosed with Alzheimer (11, 12). In addition, there also 
have been research with contrary results (13). In spite of the 
existing strong pieces of evidence on the connection 
between the alterations in CREB and the pathophysiologic 
characteristics of the AD, some points have remained 
unknown. For instance, knowing if the levels of CREB in 
Introduction: Alzheimer's disease is a neurodegenerative disease, which usually helps 
some biomarkers, such as amyloid proteins, to diagnose the disease. Therefore, the 
purpose of this study was to compare the expression of a protein binding protein to the 
adjuvant responder to circular adenosine monophosphate (CREB) in peripheral blood 
of patients to Alzheimer's and healthy elderly people as a biomarker for diagnosing 
Alzheimer. Materials and Methods: In this case-control study, 32 patients with 
Alzheimer's disease and 32 normal blood samples were taken. Using real time PCR, 
CREB expression was evaluated. Results: The mean CREB level in the case group was 
0.89 ± 0.30 and in the control group was 1.01 ± 0.03. The mean of BDNF level in the 
case group was significantly higher than the control group (P <0.001). There was no 
significant relationship between the level of CREB with age, sex, MMSE score and 
Cornell scale for depression in dementia (P> 0.05). Conclusion: Reducing CREB 
levels in people with Alzheimer's disease can be a factor in diagnosis in comparison to 
healthy people.
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the blood flow precisely reflect the same idea about the brain 
or not and also how are the CREB levels in various peripher-
al blood cells like endothelial cells and peripheral blood 
mononuclear cells which synthesize it. Minding the 
aforementioned matter, the considerable point is that the 
blood cells and the brain cells have similar genes in 80% of 
the cases of expression, therefore measuring the intracellular 
peripheral blood RNA can turn to an important and valid 
apparatus in detecting and expressing genes which are also 
expressed in central nervous system (14). According to the 
limited research about the role of the serum level of CREB 
in the early stages of Alzheimer’s disease and also to the fact 
that studying the expression of the gene of this protein in 
peripheral blood helps discover the expression of the CERB 
gene in the central nervous system, thus in this research 
project we have tried to achieve benefit from CERB as a 
biological marker in diagnosing the Alzheimer’s disease by 
measuring the expression of the gene of the CERB protein in 
peripheral blood of the individuals diagnosed with Alzheim-
er and comparing them to the healthy people and eliciting its 
connection with the severance of the symptoms and the 
duration of being infected to the disease.
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According to what was discussed, finding a marker that can 
be used for early diagnosis of Alzheimer’s disease is of 
utmost importance. Consequently, in this study, we showed 
that the amount of the CREB gene expression in the individu-
als with Alzheimer is significantly less compared to the 
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MATERIALS AND METHODS
In this case-control study, the population studied are the 
patients diagnosed with Alzheimer who are selected among 
the visiting patients to the internal department of Neurosur-
gery and clinic, and the healthy working personnel of Al 
Zahra Hospital. The factors to exclude the individuals from 
the study population for the healthy people include having a 
record of any psychiatric or neurological disease, or cancer 
or record of taking any drugs that suppress the immune 
system. The criteria for including individuals in the study 
were having the age above 50, being diagnosed by an experi-
enced neurologist with Alzheimer and receiving a lower 
mark than 24 in mini-mental state examination (MMSE). 
Moreover, in case of having cancer, being addicted to drugs, 
taking anti-depression or antipsychotic medicine in the past 
two months and addiction to alcohol or drugs and having 
stroke-induced aphasia the individual would be excluded 
from the study. The data collection method was through a 
clinical interview with the patient, taking blood sample and 
studying the gene and investigating gene expression of 
brain-derived neurotrophic factor (BDNF) using real-time 
PCR device. Cognitive decline severance was assessed 
through the MMSE questionnaire which included 11 
questions each question of which had a score between 1 to 5 
out of the total score of 30. Cognitive decline severance is 
divided to three severances using this method the score of 0 
to 17 of which represents the severe cognitive decline, 18 to 
23 represents the mild cognitive decline and 24 to 30 
represents no cognitive decline.
     The peripheral blood samples (5 ml) in the tubes contain-
ing ethylenediaminetetraceticacid (EDTA) are gathered and 
centrifuged in the room temperature for 35 minutes with the 
RESULTS
In this research, 32 patients participated in the case group 
(13 males and 19 females) and 32 individuals took part in the 
control group (15 males and 17 females). Among the two 
groups there was no significant difference based on age and 
sex (P>0.05). The average CREB blood level in the case 
group was 0.89±0.30 and in the control group, it was 
1.01±0.03, based on the independent t test the average level 
of BDNF in the case group was significantly more than the 
control group (P<0.001). In addition, the average score 
achieved in the MMSE questionnaire was 11.68±6.99, and 
the average score achieved in the Cornell scale for depres-
sion in dementia questionnaire was 12.21±6.63 (Table 1).
      There was no significant difference between the two 
sexes according to the average CREB blood level (P=0.65). 
Furthermore, the Pearson correlation indicated that there is 
no significant correlation between the CREB blood level, 
age (P= 0.61, r=-0.06), MMSE questionnaire score (P=0.44, 
r=-0.10) and the score of the Cornell scale for depression in 
dementia questionnaire (P=0.58, r=0.10).
speed of 1200. Afterwards, the layer containing lymphocyte 
is collected and is washed twice in magnesium phosphate- 
calcium buffer saline (PH=7.4). The total RNA is extracted 
from the lymphocytes. Using the spectrophotometry and 
electrophoresis gel, quantity and the purity of the extracted 
RNA is determined. One microgram of a total RNA is 
reverse transcribed in the form of cDNA using reverse 
transcription kit. The beta-actin gene is used as a housekeep-
ing gene for normalizing the target gene expression. Oligonu-
cleotide primers are ordered for beta-actin propagation and 
BDNF gene are also ordered for performing real-time PCR, 
design and synthesis. The synthesized cDNA is used for all 
real-time PCR reactions along with SYBR Green I Master 
Mix (the Genetbio kit manufacturer company from South 
Korea). Annealing heat is optimized for all primer pairs.
    After the collection of data, they were entered in the 
statistical software SPSS ver. 22, thereafter, the qualitative 
data were displayed in the form of frequency or percentage 
and the quantitative data were displayed as mean and 
standard deviation. In order to determine the normality of 
the data, Kolmogorov–Smirnov  test was used and to 
compare the qualitative data between groups, Chi Square 
test and to compare the quantitative data between groups, 
the independent t test were used. The P-value beneath 0.05 










CREB in the Peripheral Blood of Alzheimer's Patients
CONCLUSION
Therefore, referring to the studies performed on animal 
samples cannot be a good comparison criterion against the 
human samples. The current study is among the few studies 
which have measured the level of CREB peripheral protein 
gene in individuals diagnosed with Alzheimer. Due to this 
fact we can refer in this way that considering the matter in 
which the blood cells and also the brain cells have similar 
genes expression in 80 percent of the cases and the received 
results of this research based on the decrease in CREB 
peripheral protein gene expression in peripheral blood of 
individuals diagnosed with Alzheimer, these results can 
place doubt on the results of its prior made research results. 
Moreover, it is worth mentioning that based on this idea we 
can consider the CREB protein as a substantial marker in 
Alzheimer’s disease the decrease in the level of which can 
be used for early diagnosis of the Alzheimer’s disease.
Table 1. The variables studied in the study in both case and control groups
Variables Case Control P-value
67.50±4.81 0.18Age 71.34±5.86
15 (46.9%)




(59.4%) 19 19 (59.4%)
0.61Gender 
1.01±0.030.89±0.30 0.001>Blood Levels of CREB (pg/ml)
-11.68±6.99 -Mean of MMSE
-12.21±6.63 -Mean of Cornell scale for depression in dementia
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